Goldman Sachs’s Minerva Neurosciences NERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $799K | Buy |
143,954
+111,942
| +350% | +$607K | ﹤0.01% | 5394 |
|
|
2026
Q1 | $193K | Buy |
+32,012
| New | +$184K | ﹤0.01% | 6096 |
|
|
2021
Q4 | – | Sell |
-4,195
| Closed | -$58K | – | 6619 |
|
|
2021
Q3 | $58K | Sell |
4,195
-8,001
| -66% | -$120K | ﹤0.01% | 6014 |
|
|
2021
Q2 | $227K | Sell |
12,196
-107,291
| -90% | -$2.31M | ﹤0.01% | 5685 |
|
|
2021
Q1 | $2.79M | Sell |
119,487
-4,405
| -4% | -$110K | ﹤0.01% | 3655 |
|
|
2020
Q4 | $2.32M | Sell |
123,892
-22,822
| -16% | -$575K | ﹤0.01% | 3620 |
|
|
2020
Q3 | $3.73M | Buy |
146,714
+52,540
| +56% | +$1.42M | ﹤0.01% | 3123 |
|
|
2020
Q2 | $2.72M | Buy |
94,174
+81,446
| +640% | +$4.78M | ﹤0.01% | 3241 |
|
|
2020
Q1 | $613K | Buy |
12,728
+2,225
| +21% | +$134K | ﹤0.01% | 4093 |
|
|
2019
Q4 | $597K | Sell |
10,503
-253
| -2% | -$11.2K | ﹤0.01% | 4405 |
|
|
2019
Q3 | $666K | Buy |
10,756
+1,373
| +15% | +$77.8K | ﹤0.01% | 4294 |
|
|
2019
Q2 | $423K | Sell |
9,383
-3,493
| -27% | -$175K | ﹤0.01% | 4467 |
|
|
2019
Q1 | $809K | Sell |
12,876
-1,526
| -11% | -$91.7K | ﹤0.01% | 4174 |
|
|
2018
Q4 | $777K | Buy |
14,402
+1,485
| +11% | +$109K | ﹤0.01% | 4114 |
|
|
2018
Q3 | $1.3M | Buy |
12,917
+7,066
| +121% | +$531K | ﹤0.01% | 3889 |
|
|
2018
Q2 | $386K | Buy |
5,851
+2,691
| +85% | +$163K | ﹤0.01% | 4653 |
|
|
2018
Q1 | $158K | Sell |
3,160
-1,944
| -38% | -$93.4K | ﹤0.01% | 5111 |
|
|
2017
Q4 | $247K | Buy |
5,104
+1,649
| +48% | +$81.8K | ﹤0.01% | 5298 |
|
|
2017
Q3 | $210K | Sell |
3,455
-932
| -21% | -$53.5K | ﹤0.01% | 5720 |
|
|
2017
Q2 | $311K | Sell |
4,387
-351
| -7% | -$22.7K | ﹤0.01% | 5478 |
|
|
2017
Q1 | $307K | Sell |
4,738
-1,404
| -23% | -$109K | ﹤0.01% | 5444 |
|
|
2016
Q4 | $577K | Buy |
6,142
+4,856
| +378% | +$496K | ﹤0.01% | 4926 |
|
|
2016
Q3 | $145K | Buy |
+1,286
| New | +$125K | ﹤0.01% | 6025 |
|
|
2016
Q2 | – | Sell |
-5,598
| Closed | -$275K | – | 7168 |
|
|
2016
Q1 | $275K | Buy |
5,598
+1,547
| +38% | +$66.1K | ﹤0.01% | 5343 |
|
|
2015
Q4 | $197K | Sell |
4,051
-2,039
| -33% | -$85.1K | ﹤0.01% | 5727 |
|
|
2015
Q3 | $256K | Buy |
6,090
+287
| +5% | +$13.2K | ﹤0.01% | 5751 |
|
|
2015
Q2 | $269K | Buy |
5,803
+2,090
| +56% | +$89.2K | ﹤0.01% | 5853 |
|
|
2015
Q1 | $149K | Sell |
3,713
-16
| -0.4% | -$662 | ﹤0.01% | 6212 |
|
|
2014
Q4 | $180K | Sell |
3,729
-2,055
| -36% | -$78.4K | ﹤0.01% | 6239 |
|
|
2014
Q3 | $280K | Buy |
+5,784
| New | +$307K | ﹤0.01% | 5824 |
|
Other funds holding NERV
JT
VC
LGM
FCM
ABG
FCMV
Goldman Sachs's NERV Position: Q2 2026 in Review
Goldman Sachs increased its Minerva Neurosciences (NERV) stake by 350% in Q2 2026, buying an estimated $607K and bringing the position to 143,954 shares worth $799K. The position accounts for ﹤0.01% of the portfolio, ranked #5394.
Goldman Sachs first reported a position in NERV in Q3 2014 and has held it in 30 quarters since. The position peaked at $3.73M in Q3 2020. 61 funds tracked by Wall St. Rank hold NERV as of Q2 2026.
- Goldman Sachs held 143,954 shares of Minerva Neurosciences worth $799K as of Q2 2026.
- Goldman Sachs bought 111,942 Minerva Neurosciences shares in Q2 2026, an estimated $607K.
- Minerva Neurosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5394 holding.
- Goldman Sachs first reported a position in Minerva Neurosciences in Q3 2014 and has held it in 30 quarters since.
- Goldman Sachs's Minerva Neurosciences position peaked at $3.73M in Q3 2020.
- 61 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.